ACM
ACT Capital Management Portfolio holdings
AUM
$72.5M
This Quarter Return
+20.54%
1 Year Return
-33.17%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$195M
AUM Growth
–
Cap. Flow
+$195M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
56.76%
Holding
117
New
117
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
STAAR Surgical
STAA
|
$35.3M |
| 2 |
Arrowhead Research
ARWR
|
$17.3M |
| 3 |
Arcturus Therapeutics
ARCT
|
$15.4M |
| 4 |
Clearside Biomedical
CLSD
|
$12M |
| 5 |
fuboTV
FUBO
|
$8.61M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 80.26% |
| 2 | Technology | 6.22% |
| 3 | Communication Services | 5.12% |
| 4 | Financials | 2.57% |
| 5 | Consumer Staples | 1.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
STAAR Surgical
STAA
$1.36B
| $35.3M | 18.15% | +231,600 | New | +$35.3M |
|
|
2
Arrowhead Research
ARWR
$3.05B
| $17.3M | 8.88% | +208,600 | New | +$17.3M |
|
|
3
Arcturus Therapeutics
ARCT
$462M
| $15.4M | 7.92% | +455,300 | New | +$15.4M |
|
|
4
Clearside Biomedical
CLSD
$28.9M
| $12M | 6.16% | +2,462,500 | New | +$12M |
|
|
5
fuboTV
FUBO
$1.21B
| $8.61M | 4.42% | +268,000 | New | +$8.61M |
|
|
AWH
6
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| $6.36M | 3.27% | +1,130,720 | New | +$6.36M |
|
|
TRIL
7
DELISTED
Trillium Therapeutics Inc.
TRIL
| $4.51M | 2.32% | +465,000 | New | +$4.51M |
|
8
Cassava Sciences
SAVA
$110M
| $3.85M | 1.98% | +45,000 | New | +$3.85M |
|
|
ICAD
9
DELISTED
iCAD Inc
ICAD
| $3.84M | 1.98% | +222,000 | New | +$3.84M |
|
10
Unity
U
$16.7B
| $3.31M | 1.7% | +30,100 | New | +$3.31M |
|
11
Upstart Holdings
UPST
$7.05B
| $3.1M | 1.59% | +24,800 | New | +$3.1M |
|
12
Natera
NTRA
$23.1B
| $2.94M | 1.51% | +25,900 | New | +$2.94M |
|
13
The Beauty Health Co
SKIN
$264M
| $2.9M | 1.49% | +172,750 | New | +$2.9M |
|
14
Nektar Therapeutics
NKTR
$568M
| $2.77M | 1.42% | +161,500 | New | +$2.77M |
|
15
F5
FFIV
$18B
| $2.71M | 1.39% | +14,500 | New | +$2.71M |
|
16
Inhibikase Therapeutics
IKT
$134M
| $2.45M | 1.26% | +875,000 | New | +$2.45M |
|
|
AFMD
17
DELISTED
Affimed
AFMD
| $2.45M | 1.26% | +287,600 | New | +$2.45M |
|
18
Neurogene
NGNE
$264M
| $2.21M | 1.13% | +239,000 | New | +$2.21M |
|
19
Novavax
NVAX
$1.21B
| $2.19M | 1.12% | +10,300 | New | +$2.19M |
|
20
InMode
INMD
$944M
| $2.14M | 1.1% | +22,600 | New | +$2.14M |
|
21
TG Therapeutics
TGTX
$4.65B
| $2.13M | 1.1% | +55,000 | New | +$2.13M |
|
22
Aurinia Pharmaceuticals
AUPH
$1.58B
| $2.11M | 1.08% | +162,500 | New | +$2.11M |
|
|
NUAN
23
DELISTED
Nuance Communications, Inc.
NUAN
| $2.04M | 1.05% | +37,500 | New | +$2.04M |
|
|
MYOV
24
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.99M | 1.02% | +87,500 | New | +$1.99M |
|
|
IMDX
25
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $1.9M | 0.97% | +330,000 | New | +$1.9M |
|